Withdraw marketing of Durvalumab for metastatic urothelial carcinoma: CDSCO panel tells ...

Retrieved on: 2021-07-27 12:11:15

Tags for this article:

Click the tags to see associated articles and topics

Withdraw marketing of Durvalumab for metastatic urothelial carcinoma: CDSCO panel tells .... View article details on hiswai:

Excerpt

New Delhi: In a major setback to AstraZeneca Pharma India Limited., the Subject Expert Committee (SEC) of the Central Drugs Standard Control ...

Article found on: medicaldialogues.in